The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Urcosimod has received FDA fast track designation for neuropathic corneal pain, enabling expedited regulatory processes and ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

NCP is a debilitating condition characterized by severe pain and sensitivity of the eyes, face, or head, often due to nerve damage and inflammation of the cornea. Currently, there is no FDA ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...